Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs

Trial Profile

Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Antiplatelets; Fasudil
  • Indications Embolism and thrombosis; Stroke
  • Focus Therapeutic Use
  • Sponsors Asahi Kasei
  • Most Recent Events

    • 27 Apr 2010 Preliminary results suggest the primary endpoint 'Rankin scale' has not been met, according to an Asahi Kasei Pharma media release.
    • 27 Apr 2010 Primary endpoint 'Rankin scale' has not been met.
    • 03 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top